IPO - Scienture Holdings, Inc.

Form Type: S-1

Filing Date: 2025-04-04

Corporate Action: Ipo

Type: New

Accession Number: 000164117225002814

Filing Summary: Scienture Holdings, Inc. filed a registration statement with the SEC to register the resale of up to 2,643,421 shares of common stock, which includes shares convertible from secured convertible debentures issued to Selling Stockholders. The shares are being offered by Arena Finance Markets, LP and Arena Special Opportunities Partners III, LP. The registration is part of a strategy following the acquisition of Scienture, LLC, aimed at developing pharmaceutical products. The company intends to utilize proceeds from debenture conversions for general corporate purposes, while the Selling Stockholders will receive proceeds from share sales. This filing indicates a move towards an Initial Public Offering (IPO) as it seeks to publicly trade its shares on Nasdaq under the symbol SCNX, with preliminary trading values recorded.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-02-06

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225005101

Filing Summary: Scienture Holdings, Inc. is amending its registration statement on Form S-1 to register the resale of up to 4,300,000 shares of its common stock by certain selling stockholders. The shares consist of 3,925,000 shares identified as ELOC Shares, along with Initial and Additional Commitment Fee Shares totaling 320,000, plus 55,000 shares issued as a commitment fee. The company is not selling any securities in this offering and will not receive funds directly from the sales. However, it may receive up to $50 million under the ELOC Purchase Agreement, intended for general corporate and working capital purposes. The current reported sale price of the common stock on Nasdaq was $3.55 per share as of February 4, 2025, reflecting ongoing market conditions. Investors should consider the risks associated with investing in these securities, including the company's history of operating losses and regulatory challenges. This offering is subject to specific conditions as outlined in the preliminary prospectus.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-30

Corporate Action: Ipo

Type: New

Accession Number: 000149315225004193

Filing Summary: This document is an Amendment No. 2 to the Form S-1 Registration Statement filed by Scienture Holdings, Inc. for the resale of up to 4,300,000 shares of common stock. The shares are being offered by Arena Finance Markets, LP, Arena Special Opportunities Partners III, LP, and Arena Business Solutions Global SPC II, Ltd. The offering includes shares associated with various commitment fees outlined in the prospectus. The company does not anticipate receiving any proceeds from this specific offering, although it may receive up to $50 million in aggregate gross proceeds under an existing Equity Line of Credit (ELOC) Purchase Agreement. The stock is listed on Nasdaq under the symbol 'SCNX'. Investors are reminded to read the detailed risk factors related to this investment as outlined in this prospectus. The last reported sale price of the common stock was $5.07 per share as of January 8, 2025.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-14

Corporate Action: Ipo

Type: New

Accession Number: 000149315225001996

Filing Summary: Scienture Holdings, Inc. is registering the resale of up to 4,300,000 shares of its common stock, par value $0.00001, by certain Selling Stockholders. The total includes 3,925,000 ELOC shares and initial commitment fee shares issued as part of a purchase agreement with Arena Global. The Company anticipates receiving up to $50,000,000 under the ELOC Purchase Agreement. The prospectus also highlights recent acquisitions including Scienture, LLC, and the divestment of certain telehealth assets. The registration statement’s effective date is expected soon after filing with the SEC, and the company's common stock trades under the symbol 'SCNX' on NASDAQ. It emphasizes the company’s strategy in the pharmaceuticals sector, particularly in central nervous system and cardiovascular treatments.

Document Link: View Document